.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019432

« Back to Dashboard
NDA 019432 describes SPECTAMINE, which is a drug marketed by IMP and is included in one NDA. Additional details are available on the SPECTAMINE profile page.

The generic ingredient in SPECTAMINE is iofetamine hydrochloride i-123. Additional details are available on the iofetamine hydrochloride i-123 profile page.

Summary for NDA: 019432

Tradename:
SPECTAMINE
Applicant:
Imp
Ingredient:
iofetamine hydrochloride i-123
Patents:0

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength1mCi/ML
Approval Date:Dec 24, 1987TE:RLD:No

Expired Orange Book Patents for NDA: 019432

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Imp
SPECTAMINE
iofetamine hydrochloride i-123
INJECTABLE;INJECTION019432-001Dec 24, 19874,360,511► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc